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ABSTRACT
Background
Hyperparathyroidism (HPT) is a common endocrine disorder with incompletely understood
etiology, characterized by enlarged hyperactive parathyroid glands and increased serum
concentrations of parathyroid hormone and ionized calcium. We have recently reported
activation of the Wnt signaling pathway by accumulation of b-catenin in all analyzed
parathyroid tumors from patients with primary HPT (pHPT) and in hyperplastic parathyroid
glands from patients with uremia secondary to HPT (sHPT). Mechanisms that may account for
this activation have not been identified, except for a few cases of b-catenin (CTNNB1) stabilizing
mutation in pHPT tumors.
Methods and Findings
Reverse transcription PCR and Western blot analysis showed expression of an aberrantly
spliced internally truncated WNT coreceptor low-density lipoprotein receptor–related protein 5
(LRP5) in 32 out of 37 pHPT tumors (86%) and 20 out of 20 sHPT tumors (100%). Stabilizing
mutation of CTNNB1 and expression of the internally truncated LRP5 receptor was mutually
exclusive. Expression of the truncated LRP5 receptor was required to maintain the
nonphosphorylated active b-catenin level, transcription activity of b-catenin, MYC expression,
parathyroid cell growth in vitro, and parathyroid tumor growth in a xenograft severe combined
immunodeficiency (SCID) mouse model. WNT3 ligand and the internally truncated LRP5
receptor strongly activated transcription, and the internally truncated LRP5 receptor was
insensitive to inhibition by DKK1.
Conclusions
The internally truncated LRP5 receptor is strongly implicated in deregulated activation of the
WNT/b-catenin signaling pathway in hyperparathyroid tumors, and presents a potential target
for therapeutic intervention.
The Editors’ Summary of this article follows the references.
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Primary hyperparathyroidism (pHPT) is characterized by
hypersecretion of parathyroid hormone and generally also
hypercalcemia, due to one or several parathyroid tumors
(adenoma). Secondary hyperparathyroidism (sHPT) develops
in patients with uremia because of phosphate retention,
hypocalcemia, and reduced 1,25-dihydroxyvitamin D3 levels,
causing parathyroid hyperplasia and eventually development
of parathyroid tumors and hypercalcemia [1–4]. Parathyr-
oidectomy is the only considered therapy for most patients.
We recently reported aberrant b-catenin (CTNNB1) accumu-
lation in all analyzed parathyroid tumors from patients with
pHPT and in hyperplastic parathyroid glands from patients
with uremia secondary to HPT [5]. MYC, a direct target of the
Wnt/b-catenin signaling pathway in colorectal cancer cells
and established as the critical mediator of the early stages of
intestinal neoplasia [6,7], was found to be overexpressed at
the protein level in 79% of parathyroid tumors [5]. Main-
tained activity of endogenous b-catenin was found to be
necessary for the expression of MYC and cyclin D1 (CCND1),
as well as growth and survival of a unique human parathyroid
tumor cell line [8]. Overexpression of cyclin D1 has been
reported in 20%–40% of pHPT tumors [2], and over-
expression of cyclin D1 in the parathyroid glands of trans-
genic mice caused development of pHPT [9]. In a small
fraction of parathyroid adenomas, overexpression is due to
activation of the CCND1 gene by pericentromeric inversions
of Chromosome 11, involving the parathyroid hormone
(PTH) promoter [10]. Augmented cyclin D1 expression in
some parathyroid adenomas could also be a consequence of
aberrant b-catenin accumulation [5], although it remains to
be determined whether CCND1 constitutes a b-catenin target
[11] in parathyroid cells. We also reported CTNNB1 stabiliz-
ing mutations in a few cases (3 out of 20) of pHPT tumors,
while no mutation was found in uremic secondary HPT
tumors, and inactivating truncations of adenomatosis poly-
posis coli (APC) were not seen [5]. Mutation or deregulated
expression of other Wnt-signaling components leading to b-
catenin accumulation was therefore anticipated.
Dysregulated Wnt signaling with accumulation of b-catenin
in the cytoplasm/nucleus plays an important role in a variety
of human cancers. The stability of b-catenin is regulated by
Wnt ligands through a ‘‘destruction complex’’ consisting of
APC/Axin/GSK-3b/Ck1/Dvl and other factors. In the absence
of Wnt ligand, free cytoplasmic b-catenin is rapidly degraded
by the proteasome after phosphorylation of its amino
terminus at residues serine 33, serine 37, threonine 41, and
serine 45 [12–15]. Wnt ligands bind to cell-surface Frizzled
receptors and LRP5/6 coreceptors and result in changes in
phosphorylation of several intracellular signaling compo-
nents with the subsequent accumulation of nonphosphory-
lated b-catenin [16–19]. According to a current model, the
destruction complex is inactivated through recruitment of
Axin to the intracellular domain of LRP5 [20]. b-catenin
binds the LEF/TCF family of transcription factors to
positively or negatively regulate transcription of target genes.
Many mutant proteins of the Wnt signaling pathway, such as
b-catenin, APC, Axin, and beta-transducin repeat-containing
protein (b-Trcp), are associated with speciﬁc forms of cancer.
For instance, aberrant accumulation of b-catenin through
stabilizing mutations in CTNNB1 or inactivating mutations in
APC is strongly implicated in the cause of approximately 10%
and 80% of colorectal cancers, respectively [13,14]. A mutant
of LRP5 lacking the extracellular domain was demonstrated
to be constitutively active in vitro [20]. In this study, we aimed
at investigating the potential role of LRP5 in parathyroid
tumorigenesis.
Methods
Tissue Specimens
Parathyroid adenomas (n¼37) and hyperplastic glands (n¼
20) from patients with pHPT and sHPT, respectively, were
acquired from patients diagnosed and operated on in the
clinical routine. Each patient contributed with one tumor. All
57 tumors displayed aberrant accumulation of b-catenin
(unpublished data), of which 14 parathyroid adenomas and all
20 hyperplastic parathyroid glands were described previously
[5]. Normal parathyroid tissue (n ¼ 6) was obtained from
glands inadvertently removed in conjunction with thyroid
surgery where autotransplantation was not required or as
normal parathyroid gland biopsies in patients subjected to
parathyroidectomy. All tissues were intraoperatively snap-
frozen, and cryosections were used in the analyses. Written
informed consent and approval of local ethics committee was
obtained.
Detection of Normal and Internally Truncated LRP5
Transcripts by PCR and DNA Sequencing
Total RNA was extracted with TriZol Reagent (Gibco BRL,
Life Technologies) according to the manufacturer’s instruc-
tions and the RNA was subsequently treated with RQ1 DNase
I (Promega) and proteinase K. Alternatively, DNA-free RNA
was prepared using the Nucleospin RNA II kit (Macherey-
Nagel). Successful DNase treatments were established by PCR
analysis of all RNA preparations. Reverse transcription of
total DNA-free RNA was performed with random hexamer
primers using the First-Strand cDNA Synthesis kit (Amer-
sham Pharmacia Biotech) according to the manufacturer’s
instructions. cDNA was ampliﬁed by primary or nested PCR
using mRNA-speciﬁc primers spanning positions 1992–2932
of LRP5 (GenBank accession number AF064548; http://www.
ncbi.nlm.nih.gov/Genbank). A total of 1%–2% of the primary
PCR product was used for nested PCR. Primers used were the
following: forward primer, 59-CTTCACCAGCAGAGCCGC-
CATCCACAG-39; nested forward, 59-GGATCTCCCTCGA-
GACCAATAACAACG-39; and reverse, 59-CCGGGATCATCC
GACTGATG-39. The PCR ampliﬁcations were performed
with cDNA, 25 pmol of each primer, 0.2 mM dNTPs, 13 PCR
buffer, 1.5 mM MgCl2, and 0.25 U Platinum Taq DNA
polymerase (Invitrogen). The PCR conditions were: denatu-
ration at 95 8C for 60 s, followed by 40 cycles of denaturation
for 20 s, annealing at 58 8C for 20 s and extension at 72 8C for
90 s, and a ﬁnal extension at 72 8C for 7 min. An annealing
temperature of 61 8C and 40 cycles were used for nested
ampliﬁcation. Two LRP5wt and six randomly chosen trun-
cated LRP5 cDNA fragments from parathyroid tumors, as
well as from sHPT-1 cells, were cloned into pCRII-TOPO
(Invitrogen), and sequenced on ABI 373A using the ABI Prism
Dye Terminator Cycle Sequencing Ready Reaction kit
(Applied Biosystems). All fragments encoded an open reading
frame, and the seven truncated fragments contained the same
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were purchased from BD Biosciences Clontech and Ambion.
Cell Growth Determination and Flow Cytometry
Cells (2 3 10
5) were distributed onto 35-mm dishes in
DMEM/10% fetal bovine serum and subsequently harvested at
the indicated time points. The number of viable cells were
determined by using the NucleoCounter (ChemoMetec). Cells
were collected at 84 h after siRNA transfection and incubated
with FITC-labeled annexin V to assess phosphatidylserine
externalization as a marker for apoptosis.
Propidium iodide was added to distinguish tumor cells that
had lost membrane integrity. Cells were analyzed by ﬂow
cytometry on a Becton Dickinson FACS Calibur ﬂow
cytometer (BD Biosciences).
RT-PCR Analyses
cDNA was prepared as described above. The following
mRNA-speciﬁc PCR primers and labeled probes (59FAM-
sequence–39TAMRA) were used for quantitative real-time
RT-PCR analysis. For LRP5wt: forward: 59-CCTGAAGACCAT-
CAGCCGCG-39; reverse, 59-CCCGCTCCTGACCCAGCATG-
39; and probe, 59-TCCCACCAAGGGCTACATCTACTG-39.
For LRP5tot: forward, 59-ATCGACTGTATCCCCGGGGC-39;
reverse, 59-CACCACGCGCTGGCACACAA-39; and probe, 59-
CGGACTGTGACGCCATCTGCCTGC-39. For MYC: forward,
59-AAGACTCCAGCGCCTTCTCTCCGT-39; reverse, 59-
TGGGCTGTGAGGAGGTTTGCTGTG-39; and probe, 59-AGC-
GACTCTGAGGAGGAACAAGAA-39. For 28S rRNA, the Ri-
bosomal RNAControl Reagents (VIC probe) was used (Applied
Biosystems). PCR reactions were performed on ABI PRISM
7700 Sequence Detection System or MyiQ Single-Color Real-
Time PCR Detection System (Bio-Rad) using the TaqMan PCR
core Reagent Kit (Applied Biosystems). Each cDNA sample was
analyzed in triplicate. Standard curves for the expressed genes
were established by amplifying a puriﬁed PCR fragment
covering the sites for probes and primers. Messenger RNA-
speciﬁcPCRprimers for WNT1 were asdescribed [21]. Primers
for WNT3 were as follows: forward, 59-GGCTGTGACTCG-
CATCATAA-39; reverse, 59-CAGCAGGTCTTCACCTCACA-39.
Transfection Experiments, Western Blotting, and
Immunoprecipitation
sHPT-1 parathyroid tumor cells [8] were transfected with
siRNA at least in triplicates at 2 3 10
5 cells/35-mm dish with
jetSI-ENDO according to the manufacturer’s recommenda-
tions (Poly-Plus-Transfection SAS). The following siRNAs
were used: control nonsilencing siRNA (Qiagen Operon),
siLRP5D666–809; 59-TAACAACGACCUCACCAUUdTdT-39
and 59-AAUGGUGAGGUCGUUGUUAdTdT-39 (synthesized
by Thermo Electron, Ulm, Germany), siLRP5wt; 59-CAACCA-
CAUCUACUGGACAdTdT-39 and 59-UUCCAGUAGAUGUG-
GUUGdTdT-39 (Thermo Electron), siLRP5tot; stealth 59-
CCUGCAUGGACUGAGGAACGUCAAA-39 and stealth 59-
UUUGACGUUCCUCAGUCCAUGCAGG-39, control siLRP5-
tot; stealth 59-CCUGGUAGUCAAGGAUGCACCGAAA-39
and stealth 59-UUUCGGUGCAUCCUUGACUACCAGG-39
(Invitrogen). A very high transfection efﬁciency (virtually all
cells) was obtained for sHPT-1 cells by this protocol [8]. HeLa
cells were transfected in the same manner, with a transfection
efﬁciency of approximately 90% (data not shown). Condi-
tioned medium was produced in HEK293T cells transiently
transfected for 24 h by pCIN4/Wnt1 (kind gift from Dr. R.
Kemler), pLNC Wnt-3HA (kind gift from Dr. J. Kitajewski),
PON-Wnt-3a (kind gift from Dr. B. Williams), or pCS2/Dkk1
(kind gift from Dr. S. Y. Sokol) using Fugene 6 (Roche
Diagnostics). sHPT-1 cells were transfected with the FOP-
FLASH or TOPFLASH TCF [22] luciferase reporter (Upstate)
and the CMV-LacZ reference plasmid [23] for 24 h using
jetPEI (Poly-Plus-Transfection SAS). In some experiments,
TOPFLASH was transfected; transfection of siRNA to the
same culture was done after 24 h and cells were harvested 96
h later. Luciferase and b-galactosidase activities were deter-
mined luminometrically, and luciferase activity was normal-
ized for differences in b-galactosidase activity. Expression
plasmid LRP5D666–809 was constructed by replacing the
XhoI/KpnI fragment of pcDNA3.1/LRP5 and pcDNA3.1/V5-
His/LRP5 (expressing tagged LRP5) with a XhoI/KpnI-
digested PCR fragment harboring the deletion D666–809.
Western blotting analyses were done on extracts prepared in
Cytobuster Protein Extract Reagent (Novagen) supplemented
with Complete protease inhibitor cocktail (Roche Diagnos-
tics) or on a cytosolic protein extract [24]. Anti-V5–HRP
antibody (Invitrogen), anti-active–b-catenin [25] mouse
monoclonal antibody (Upstate; catalog number 05–665),
anti-LRP5 goat polyclonal antibody (Santa Cruz Biotechnol-
ogy; catalog number sc-21390), anti-actin goat polyclonal
antibody, and anti–b-tubulin rabbit polyclonal antibody
(Santa Cruz Biotechnology) were used. For tumor specimens,
protein extracts for Western blotting were prepared from 10
consecutive frozen tissue sections (6 lm) in Cytobuster
Protein Extract Reagent (Novagen) supplemented with
Complete protease inhibitor cocktail (Roche Diagnostics).
For immunoprecipitations, cells were resuspended in 300 ll
buffer (50 mM Tris [pH 8.0], 150 mM Nacl, 0.5% NP-40, 50
mM NaF, and 1 mM EDTA, supplemented with Complete
protease inhibitor cocktail), kept on ice for 20 min, and
centrifuged for 20 s at 14,000 rpm. After addition of 20 ll
anti-LRP5 goat polyclonal antibody (Santa Cruz Biotechnol-
ogy; catalog number sc-21390), the lysate was incubated
overnight at 4 8C with gentle agitation. A total of 50 ll
Protein G PLUS–Agarose (Santa Cruz Biotechnology; catalog
number sc-2002) was then added to the lysate and further
incubated for 6 h. After centrifugation, the sample was boiled
in 40 ll Laemmli sample buffer for 10 min and 10–20 ll was
subjected to Western blotting analysis.
ChIP Assay
Chromatin immunoprecipitation (ChIP) of transfected
cells was performed using a protocol from Upstate, but with
immunoprecipitation conditions as described [26]. The anti-
active–b-catenin mouse monoclonal antibody [25] was used
(Upstate; catalog number 05–665) and MYC promoter DNA,
containing TCF-4 binding site 2 [22], was PCR ampliﬁed in
the linear range by the following primers: forward, 59-
ACGTGGCAATGCGTTGCTGGG-39; and reverse, 59-ACACA-
GAGAACGCACTGCGCG-39.
Mouse Xenograft Model
Female Fox Chase severe combined immunodeﬁciency
(SCID) mice (2- to 3-wk-old) were used (Taconic). The mice
were anesthetized with isoﬂurane (Forene; Abbott ) during
the manipulations. One ﬂank or both ﬂanks of each animal
were injected subcutaneously (total 200 ll) with sHPT-1 cells
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Truncated LRP5 Receptor in HPT Tumorstogether (1:1) with BD Matrigel Matrix (BD Biosciences
Clontech) after transfection of 10
6 cells for 24 h. The animals
were monitored every day and humanely killed after 8–9 wk.
The animal experiments were approved by the Uppsala
University board of animal experimentation and were
performed according to the United Kingdom Coordinating
Committee on Cancer Research guidelines for the welfare of
animals in experimental neoplasia [27].
Statistical Analysis
Unpaired t test was used for all statistical analyses. Values
are presented as arithmetrical mean 6 standard error of the
mean. A p-value below 0.05 was considered signiﬁcant.
Results
An Internally Truncated LRP5 Receptor Is Expressed in
Parathyroid Tumors
A shorter LRP5 transcript (LRP5D666–809) was detected in
32 out of 37 pHPT tumors (86%) and 20 out of 20 sHPT
tumors (100%) by using RT-PCR primers located in exons 9
and 13 of LRP5 (Figure 1A). Of the analyzed parathyroid
tumors (n ¼ 57) which all displayed aberrant cytoplasmic/
nuclear accumulation of b-catenin ([5] and unpublished data),
four pHPT tumors without the LRP5D666–809 transcript
harbored the stabilizing mutation of the b-catenin exon 3
(S37A), and one pHPT tumor had neither. Three out of the
four tumors with b-catenin mutation were reported previ-
ously, and the one tumor without b-catenin mutation or the
LRP5D666–809 transcript displayed wild-type APC expres-
sion [5]. Six normal parathyroid tissues and a panel of 17
normal tissues expressed only the normal LRP5 (LRP5wt)
transcript (Figure 1B). Accordingly, a smaller LRP5 protein
was detected by immunoprecipitation followed by Western
blot analysis of the parathyroid tumors expressing the
LRP5D666–809 transcript and in the human parathyroid
tumor cell line sHPT-1 (Figure 1C), where CTNNB1 is not
mutated in exon 3 [8]. The expression level of the smaller
form of LRP5 varied in relation to LRP5wt among the
analyzed tumors. In the sHPT-1 cell line, it was expressed at a
higher relative level (see also Figure 2C). Only the LRP5wt
receptor was detected in HeLa cells (Figure 1C), which did
not express the truncated LRP5D666–809 transcript (unpub-
lished data). No apparent relationships between expression of
LRP5D666–809 or CTNNB1 stabilizing mutation and clinical
characteristics, such as glandular weight or serum levels of
parathyroid hormone or calcium, were found.
The tumor-associated shorter transcript LRP5D666–809
contained an in-frame deletion of 142 amino acids (D666–
809), encompassing the third YWTD b-propeller domain
[28,29] between the second and third epidermal growth factor
repeats of LRP5 (Figure 1D). The deletion (D666–809) was
ﬂanked by imperfect direct repeat sequences with putative
cryptic donor and acceptor RNA splice sites located in exons
9 and 11, respectively (Figure 1D). The 59 putative cryptic
splice site (Ac-GTG) related to the consensus sequence of
major-class introns and the 39 cryptic splice (AC-cT) related
more to the minor-class [30]. The genomic sequences of exon/
intron junctions and branch points in question as well as
exons 10 and 11 did not reveal any abnormalities in several
tumors. Also, no deletion was noted by Southern blotting of
genomic DNA (unpublished data). The LRP5 internal
truncation is most likely the result of cryptic splice site usage.
The Internally Truncated LRP5 Receptor Contributes to
Active b-Catenin Signaling
To investigate the functional consequences of LRP5D666–
809 expression, if any, speciﬁc and control siRNAs were
efﬁciently transfected [8] to the recently established unique
human parathyroid tumor cell line sHPT-1. Three different
siRNAs against LRP5 mRNA were used (Figure 2A): one
against the LRP5wt transcript (siLRP5wt), one against the
internally truncated transcript (siLRP5D666–809), and one
recognizing both the LRP5wt and LRP5D666–809 transcripts
(siRNAtot). siLRP5wt was directed to exon 10, which was
excluded from the truncated transcript (Figure 1A);
siLRP5D666–809 was directed against the unique sequence
created at the aberrant exon junction; and siRNAtot was
directed to exon 13, which was present in both LRP5
transcripts (Figures 1D and 2A). A nonsilencing siRNA
(control siRNA) and a mutant siRNAtot (control siRNAtot)
were also used. Speciﬁcity and silencing potential of the
siRNAs were ascertained both at the mRNA and protein level
(Figure 2B and 2C).
Transfection of siLRP5D666–809 reduced the nonphos-
phorylated active b-catenin level markedly as well as
decreased the growth of sHPT-1 cells. siLRP5wt showed a
tendency toward a lowered b-catenin level, but no signiﬁcant
effect on cell growth was observed (Figure 3A and 3B). In
agreement with these results, transfection of siRNA speciﬁc
for both LRP5 transcripts (siLRP5tot) resulted in similar
diminished b-catenin expression and cell growth as for
siLRP5D666–809 (Figure 3A and 3B). The growth of HeLa
cells, which did not express the internally truncated LRP5
receptor (Figure 1C), was not affected by siRNA transfections
(Figure 3B). As shown previously for siRNA to CTNNB1 [8],
sHPT-1 cells transfected with siLRP5D666–809 but not with
control siRNA showed accumulation of dead cells as well as a
Figure 1. An Internally Truncated LRP5 Receptor Is Expressed in Parathyroid Tumors
(A) RT-PCR analysis of RNA from pHPT tumors (n ¼ 20) and sHPT tumors (n ¼ 20) using primers located in exons 9 and 13 of LRP5. The wild-type or
truncated LRP5 mRNAs were detected by primary PCR for most of the tumors or with nested PCR using an additional overlapping forward primer. The
truncation comprised the last 93 bp of exon 9, all 227 bp of exon 10, and the first 106 bp of exon 11.
(B) Nested RT-PCR of normal parathyroid tissue (n¼ 6), and parathyroid tumor cell line sHPT-1 [8] as marker (top panel). Nested RT-PCR analysis of 17
normal tissues, and the parathyroid tumor pHPT21 as marker (lower panel).
(C) Immunoprecipitation followed by Western blot analysis of LRP5. Transiently expressed (HEK293T cells) LRP5 and LRP5D666–809 shown as size
markers. sHPT-1, human parathyroid tumor cell line [8]; pHPT, pHPT tumor. The lower panel shows additional pHPT tumor samples analyzed on a 5%
SDS–polyacrylamide gel, where the proteins separate more clearly.
(D) A schematic structure of LRP5 is shown. The truncated mRNA contains an in-frame deletion of LRP5 between amino acids 666 and 809 (D666–809),
encompassing the third YWTD b-propeller domain. The truncation (D666–809) is flanked by imperfect direct repeat sequences (horizontal arrows) with
putative cryptic donor (Ac-GTG) and acceptor (AC-cT) RNA splice sites in exons 9 and 11, respectively (arrows). The D666–809 is between nucleotide
positions 2039 and 2466 of the LRP5 mRNA (GenBank accession no. AF064548).
doi:10.1371/journal.pmed.0040328.g001
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Truncated LRP5 Receptor in HPT TumorsFigure 2. Specificity and Efficiency of siRNAs Transiently Transfected to the sHPT-1 Parathyroid Tumor Cell Line
(A) Locations of siRNAs and probes for quantitative real-time PCR. tot mRNA PCR probe determines both LRP5wt and LRP5D666–809 transcripts.
(B) Expression of LRP5wt and LRP5tot mRNA assessed by quantitative real-time PCR. (C) Immunoprecipitation and Western blot analysis of LRP5.
doi:10.1371/journal.pmed.0040328.g002
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Truncated LRP5 Receptor in HPT TumorsFigure 3. Maintained Expression of the Internally Truncated LRP5 Receptor Is Required for Accumulation of Nonphosphorylated b-Catenin and
Continued Cell Growth
(A) Western blot analysis of active b-catenin [25], 60 h after transfection. The b-catenin–actin signal ratio is shown.
(B) Effects on sHPT-1 cell growth. HeLa cells were used as control for toxic effects. *p , 0.05.
(C) Flow cytometry analysis of sHPT-1 cells at 84 h after transfection after staining with annexin V–FITC and propidium iodide. Accumulation of dead
cells in the upper left quadrant; population of late apoptotic cells (upper right quadrant) and early apoptotic cells (lower right quadrant).
doi:10.1371/journal.pmed.0040328.g003
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Truncated LRP5 Receptor in HPT Tumorssmaller population of apoptotic cells 84 h after transfection
(Figure 3C). Furthermore, the endogenous b-catenin activity
in sHPT-1 cells (11-fold), as measured by FOPFLASH/TOP-
FLASH TCF/b-catenin luciferase reporter transfection, was
dependent on maintained expression of LRP5D666–809 and
not of LRP5wt (Figure 4A). Dependence on maintained
expression of LRP5D666–809 was also observed for expres-
sion of the endogenous b-catenin target gene MYC [22], which
is commonly overexpressed in parathyroid tumors [5], as the
MYC mRNA level was signiﬁcantly reduced in sHPT-1
parathyroid cells transfected with siLRP5D666–809 and
siLRP5tot, but not with siLRP5wt, control siRNA, and control
siLRP5tot (Figure 4A). Expression of MYC in sHPT-1 cells has
been shown previously to depend on b-catenin [8]. Thus,
maintained expression of the internally truncated LRP5
receptor in sHPT-1 cells appeared necessary for accumula-
tion of transcriptionally active b-catenin, continued cell
growth, and MYC expression. An effect of the internally
truncated LRP5 receptor on b-catenin signaling was further
substantiated by experiments in HEK293T cells. Transient
expression (Figure 4B) of LRP5D666–809 and not of LRP5wt
in these cells resulted in increased level (5-fold) of non-
phosphorylated active b-catenin (Figure 4C), a 5-fold increase
of endogenous MYC mRNA expression (Figure 4D), and
enhanced association (4-fold) of b-catenin to the MYC
promoter, as revealed by ChIP (Figure 4E).
WNT3 Ligand and the Internally Truncated LRP5 Receptor
Strongly Activate Transcription with Impaired DKK1
Inhibition
The effects of WNT ligand stimulation of the LRP5wt and
LRP5D666–809 receptors were determined by transient
cotransfection of the TOPFLASH TCF/b-catenin luciferase
reporter and the LRP5 receptor expression vectors to sHPT-1
cells, followed by incubation in WNT1, WNT3, or WNT3A
conditioned medium. Transfected LRP5D666–809 displayed
activation of b-catenin driven transcription in sHPT-1 cells
(9-fold), and transcription was most prominently stimulated
(80-fold) in the presence of WNT3 ligand, where it was 4-fold
higher than for LRP5wt (Figure 5A). In addition, only WNT3
stimulated the endogenous b-catenin activity (9-fold).
WNT3A ligand stimulated transcription only in the presence
of LRP5wt (10-fold), and WNT1 showed no effects. WNT3 but
not WNT1 was expressed by RT-PCR in parathyroid tumors
(Figure 5B).
Several amino acid residues in the deleted part of LRP5
(D666–809) were shown to be required for inhibition of b-
catenin activity by the WNT antagonist DKK1 [31]. Therefore,
we examined the effect of DKK1, which is expressed in
parathyroid tumors (unpublished data) on WNT3-stimulated
b-catenin activity in sHPT-1 cells. The presence of DKK1 in
the culture medium resulted in inhibition of WNT3 activa-
tion in HEK293T control cells as expected (Figure 5D), but
not in sHPT-1 cells (Figure 5C). In agreement with these
results, WNT3-induced TOPFLASH transcription was in-
hibited by DKK1 in HEK293T cells cotransfected with
LRP5wt and not with LRP5D666–809 (Figure 5D). Also, the
activity of LRP5D666–809 in unstimulated cells (7-fold) was
insensible to DKK1. In contrast to sHPT-1 cells (Figure 5A),
HEK293T cells responded to WNT1-conditioned medium (7-
fold) and was sensitive to DKK1 inhibition as expected.
However, the small increase of LRP5D666–809 activity in the
presence of WNT1 (1.7-fold) was insensible to DKK1 (Figure
5D). The impaired DKK1-mediated antagonism of b-catenin
activity may contribute to overall signaling of the internally
truncated LRP5 receptor.
Inhibition of Tumor Growth in SCID Mice
The in vivo growth properties of sHPT-1 cells were
evaluated in a xenograft SCID mouse model. Signiﬁcant
tumor growth inhibition was observed in transplants of cells
when pretransfected with siLRP5D666–809 or siLRP5tot, but
not with siLRP5wt or control siRNA (Figure 6A and 6B). Thus,
the internally truncated LRP5 receptor appeared to be
required for tumor growth in this animal model. Combina-
tion of the very high siRNA transfection efﬁciency of sHPT-1
cells [8] and generally prolonged gene silencing in slowly
dividing cells [32] are likely prerequisites for the sustained
tumor growth inhibition observed 8–9 wk after transplanta-
tion.
Discussion
b-catenin accumulation has been observed by us in all so
far analyzed parathyroid tumors of primary origin and
hyperplastic parathyroid glands of HPT secondary to uremia
([5] and this work), strongly suggesting dysregulated WNT/b-
catenin signaling as a common pathogenic pathway for these
different conditions. We reported CTNNB1-stabilizing muta-
tions in a few cases (3 out of 20) of pHPT tumors, while no
mutation was found in uremic secondary HPT tumors, and
inactivating truncations of APC were not seen [5]. Recently,
parathyroid adenomas from 97 patients with pHPT who had
undergone parathyroidectomy in the United States were
analyzed regarding CTNNB1-stabilizing mutations in exon 3
[33]. In agreement with one previous smaller study of
Japanese patients [34], no mutations were identiﬁed. Taken
together, these results indicated a low CTNNB1 mutation
frequency in pHPT tumors [35]. We are currently analyzing a
large number of additional pHPT tumors from Swedish
patients. A few additional tumors with CTNNB1-stabilizing
mutations has been found so far, suggesting an overall
mutation frequency of approximately 6% (Bjo ¨rklund et al.,
unpublished data). This frequency is slightly lower than that
Figure 4. The Internally Truncated LRP5 Receptor Regulates b-Catenin–Driven Transcription
(A) Transient cotransfections of FOPFLASH or TOPFLASH TCF/b-catenin reporters, the CMV-LacZ reference plasmid, and indicated siRNAs to sHPT-1 cells
(left panel). FOPFLASH contains mutated binding sites for TCF factors, while TOPFLASH does not [22]. Luciferase activities were normalized to b-
galactosidase activities. Effects on endogenous MYC expression in sHPT-1 cells (right panel). *p , 0.05.
(B) Western blot analysis of V5-tagged LRP5 and LRP5D666–809 transiently transfected to HEK293T cells. LRP5 and LRP5D666–809 were expressed at
similar levels.
(C) Western blot analysis of cytosolic nonphosphorylated active b-catenin in HEK293T cells, 24 h after transfection.
(D) Endogenous MYC expression in transfected HEK293T cells. *p , 0.05.
(E) ChIP of the MYC promoter in transfected HEK293T cells. An anti-active–b-catenin monoclonal antibody was used [25].
doi:10.1371/journal.pmed.0040328.g004
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Truncated LRP5 Receptor in HPT TumorsFigure 5. WNT3 Ligand and the Internally Truncated LRP5 Receptor Strongly Activates Transcription of the TOPFLASH TCF/b-Catenin Luciferase
Reporter with Impaired DKK1 Inhibition
(A) sHPT-1 cells cotransfected with TOPFLASH, LRP5wt, or LRP5D666–809 expression vectors and CMV-LacZ reference plasmid, followed by incubation
in WNT1, WNT3, or WNT3A conditioned medium (CM). CM was from HEK293T cells transfected transiently with expression vectors for the various WNT
ligands. The 11-fold (Figure 4A) endogenous b-catenin activity is set to 1 (unstimulated, empty vector).
(B) Representative RT-PCR analysis of RNA from three pHPT and three sHPT tumors using primers for WNT3. No expression of WNT1 was detected by the
conditions used [21].
(C) Cotransfection of TOPFLASH and CMV-LacZ reference plasmid to sHPT-1 cells. Incubation in WNT3 and DKK1 CM.
(D) Cotransfection of TOPFLASH, CMV-LacZ reference plasmid, and LRP5wt or LRP5D666–809 expression vectors to HEK293T cells followed by
incubation in WNT1, WNT3, or DKK1 CM. HEK293T cells do not express the internally truncated LRP5 receptor.
doi:10.1371/journal.pmed.0040328.g005
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Truncated LRP5 Receptor in HPT Tumorsobserved for colorectal cancers, in which approximately 10%
of the tumors harbored missense mutations or interstitial
deletions of exon 3 [13,14].
Several lines of experimental evidence presented here
support a fundamental role of the internally truncated LRP5
receptor in regulating b-catenin–driven transcription in
parathyroid tumor cells. The truncated LRP5 receptor was
frequently expressed both in parathyroid tumors of primary
origin (86%) and in hyperplastic parathyroid glands of HPT
secondary to uremia (100%). Of all 57 analyzed parathyroid
tumors with accumulated b-catenin, 52 expressed the
internally truncated LRP5 receptor without CTNNB1-stabi-
lizing mutations, four tumors had CTNNB1-stabilizing muta-
tions but no truncated LRP5 receptor, and 1 tumor displayed
neither aberration. Thus, it seems that mutation of CTNNB1
and expression of LRP5D666–809 is mutually exclusive.
All reported LRP5 missense mutations, which cause a high-
bone-mass phenotype, are located before the ﬁrst epidermal
growth factor–like repeat in the amino terminal part of the
receptor, not including the third YWTD b-propeller domain,
which is absent in the truncated LRP5 receptor. Several
mutations of LRP5 known to cause osteoporosis-pseudoglio-
ma syndrome is located within amino acids 666–809, high-
lighting a functional role for this part of the protein [36].
Figure 6. siRNAs to the Internally Truncated LRP5 Receptor Inhibit Tumor Growth in Xenografted SCID Mice
(A) Injection of sHPT-1 cells pretransfected for 24 h with siLRP5D666–809 or control siRNA. Arrows indicate representative parathyroid tumor growth at
site of transplantation.
(B) Parathyroid tumors from SCID mice (n¼35) injected with sHPT-1 cells pretransfected for 24 h with the indicated siRNAs were excised and weighed.
*p , 0.05. The animals were monitored every day and killed after 8–9 wk.
doi:10.1371/journal.pmed.0040328.g006
PLoS Medicine | www.plosmedicine.org November 2007 | Volume 4 | Issue 11 | e328 1839
Truncated LRP5 Receptor in HPT TumorsOsteoporosis-pseudoglioma mutations seem to cause varying
degree of reduced Wnt or Norrin signaling by unknown
mechanisms, as determined by the TOPFLASH reporter assay
[37]. Clearly, the deletion of 142 amino acids in LRP5D666–
809 and a missense mutation in the same part of the receptor
have opposite effects. A missense mutation may for example
interfere with binding of cell-type–speciﬁc factor(s), while a
larger deletion may result in structural changes of the
receptor with a different impact on cofactor interactions
and signal outcome. The mechanism(s) by which the
internally truncated LRP5 receptor activates b-catenin
signaling in tumor cells remains to be elucidated, but may
involve impaired inhibition by DKK1. The WNT3 ligand
activated transient transcription more strongly in the
presence of LRP5D666–809 than LRP5wt, possibly suggesting
favored interaction of WNT3 with the internally truncated
receptor. We emphasize that the conditioned medium of
WNT1, WNT3, WNT3A, and DKK1 used throughout this
study might contain uncharacterized signaling molecules
induced by the WNTs or DKK1.
RNA splicing defects in cancer are common, but seem
rarely to be caused by somatic mutations in splice sites and
regulatory elements. Alternative splicing may potentially
present as a diagnostic marker [38,39]. Interestingly, aberrant
splicing between direct repeat sequences with potential
cryptic splice sites and without mutations in selected parts
of the gene has been described also for the MDM2 oncogene
in breast cancer [40]. We found no mutations or poly-
morphisms in the sequenced exons/branch points/intron–
exon junctions of the LRP5 gene in the analyzed tumors that
potentially could explain the aberrant splicing. Mutations in
other areas of the LRP5 gene affecting splicing speciﬁcity,
accuracy, or efﬁciency, or perhaps more likely interference of
trans-acting factors of the splicing machinery, are other
possibilities. Alternative splicing may be affected in a splicing
factor concentration-dependent manner [41], and this may
also apply to aberrant splicing in tumors. Identiﬁcation of
splicing oncogenes or splicing tumor suppressor genes is
being pursued.
The results support a fundamental role of the aberrantly
spliced internally truncated LRP5 receptor in activating
WNT/b-catenin signaling in parathyroid tumor cells. LRP5
receptors could be attractive targets for the development of
antitumor drugs that speciﬁcally inactivate the truncated
receptor and leave the normal protein unaffected.
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Editors’ Summary
Background. The parathyroid glands—four rice-sized glands in the
neck—maintain a normal calcium balance in the body, to maintain
strong bones and essential cellular functions. The glands release
parathyroid hormone as a response to a decrease in blood calcium
level. By stimulating calcium release from bone and its absorption in the
gut, parathyroid hormone restores the blood calcium level. However,
100,000 new individuals in the US develop hyperparathyroidism (HPT)
annually, characterized by enlarged, overactive parathyroid glands and
high blood levels of calcium. Primary HPT (pHPT) is usually caused by a
benign tumor (a non-life-threatening growth) in one of the parathyroid
glands. Secondary HPT (sHPT) occurs in response to calcium regulatory
disturbances, linked to vitamin D deficiency, and more or less invariably
develops in patients with uremic kidney disease.
Why Was This Study Done? HPT is usually treated by surgical removal
of the enlarged parathyroid glands, which is done with great efficiency.
However, ideally, doctors would like to know what drives the overgrowth
of the parathyroid glands to be able to develop drugs for treatment or
disease prophylaxis. Researchers recently reported that the cells in
enlarged parathyroid glands from patients with HPT contain high
amounts of b-catenin. This protein is part of the Wnt signaling pathway,
which has been found to be disrupted in many tumor entities in other
organs. In the absence of Wnt proteins, a group of proteins called the b-
catenin destruction complex marks b-catenin so that it is rapidly
destroyed. When Wnt proteins bind to a cell-surface receptor called
Frizzled and a coreceptor called LRP5, the destruction complex is
inhibited and b-catenin accumulates. This accumulation induces the
production of other proteins (in particular, c-Myc) that stimulate cell
growth and division. The accumulation of b-catenin in the enlarged
parathyroid glands of patients with HPT could, therefore, significantly
contribute to the overgrowth of their glands—but what causes b-catenin
accumulation? In this study, the researchers have investigated this
question to try to identify a target for drugs to treat HPT.
What Did the Researchers Do and Find? The researchers looked for
genetic changes (mutations) in b-catenin that stabilize the protein and
measured the expression of LRP5 in abnormal parathyroid gland tissue
from 37 patients with pHPT and 20 with uremia and sHPT. All the
samples contained high levels of b-catenin, but only four contained a b-
catenin–stabilizing mutation. All the sHPT samples and 32 pHPT samples
(but none of the samples containing the b-catenin stabilizing mutation)
expressed a mutated LRP5, with the central region deleted. To
investigate the functional consequences of this internally deleted LRP5
protein, the researchers used a technique called RNA interference to
block its expression in a human parathyroid tumor cell line. They found
that expression of the mutated, short LRP5 is required for accumulation
of b-catenin, expression of c-Myc, and continued growth of the cell line
in test tubes and in animals.
What Do These Findings Mean? The accumulation of b-catenin in all
the enlarged parathyroid glands examined so far strongly implicates
abnormal Wnt/b-catenin signaling in the development of pHPT and
sHPT. These new findings identify which part of the signaling pathway is
altered. The expression data and functional data together suggest that
an internally deleted LRP5 coreceptor is often responsible for the
accumulation of b-catenin. The functional data also show that expression
of shortened LRP5 is necessary for the abnormal growth of parathyroid
tumor cells. Exactly how the internally deleted coreceptor activates b-
catenin signaling in parathyroid gland cells, or why a shorter-than-
normal LRP5 is made, are not yet known. However, because these
findings indicate that internally deleted LRP5 has a fundamental role in
activating Wnt signaling in HPT, drugs that inactivate this aberrant
protein but leave the normal protein unscathed might provide a
nonsurgical treatment for this common hormone disorder.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040328.
  MedlinePlus has encyclopedia pages on hyperparathyroidism, primary
hyperparathyroidism, and secondary hyperparathyroidim (in English
and Spanish)
  Information is available for patients from the US National Institute of
Diabetes and Digestive and Kidney Diseases on hyperparathyroidism,
which includes links to organizations that help people with
hyperparathyroidism
  Wikipedia maintains pages on Wnt signaling pathway and on
b-catenin (note that Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
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